Cresco Labs Financials

Cresco Labs (CRLBF) reported diluted earnings per share of -$0.38 for fiscal year 2025. This represents a -72.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cresco Labs (CRLBF) had EBITDA of $20.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Cresco Labs (CRLBF) had $57.9M in cash and equivalents against $417.1M in long-term debt.

Cresco Labs (CRLBF) had a gross margin of 49.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Cresco Labs (CRLBF) had an operating margin of -4.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Cresco Labs (CRLBF) had a net profit margin of -20.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Cresco Labs (CRLBF) has a return on equity of -39.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Cresco Labs (CRLBF) generated $37.8M in free cash flow during fiscal year 2025. This represents a -66.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Cresco Labs (CRLBF) generated $72.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Cresco Labs (CRLBF) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.

Cresco Labs (CRLBF) invested $35.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Cresco Labs (CRLBF) had a current ratio of 2.59 as of fiscal year 2025, which is generally considered healthy.

Cresco Labs (CRLBF) had a debt-to-equity ratio of 1.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Cresco Labs (CRLBF) had a return on assets of -11.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Cresco Labs (CRLBF) has an Altman Z-Score of -0.95, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Cresco Labs (CRLBF) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Cresco Labs (CRLBF) reported a net loss of $135.4M while generating $72.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Cresco Labs (CRLBF) reported an operating loss of $28.0M against $41.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.